Work

Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer

Year: 2024

Type: article

Study design: Observational Study

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2024.06.014

Authors: A. Di Federico, S.L. Alden, J.W. Smithy, B. Ricciuti, J.V. Alessi, X. Wang, F. Pecci, G. Lamberti, M.M. Gandhi, V.R. Vaz, L.F. Spurr, L.M. Sholl, K.L. Pfaff, S.J. Rodig, Y.Y. Li, A.D. Cherniack, M. Nishino, B.E. Johnson, M.M. Awad

Institutions: Dana-Farber Cancer Institute, Johns Hopkins University, Johns Hopkins Medicine, Memorial Sloan Kettering Cancer Center, Harvard University, University of Chicago, Brigham and Women's Hospital, Broad Institute, Massachusetts Institute of Technology, Dana-Farber Brigham Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4400157108

FWCI: 8.388

Cites: 28

Cited by: 55

Related to: 10